SavedAdd your journal

Journals / Fabad Eczacılık Bilimler Dergisi / 2023 / Cilt: 48 Sayı: 2

Interaction of Statins with Grapefruit Juice

Müge ATEŞ
Selma ŞAHİN
Pages
337–358
Publication Date
2023-08-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, patients using statins are generally advised to avoid grapefruit juice consumption.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Grapefruit juice, which discovered to interact with felodipine for the first time, is now known to interact with more that 80 drugs.
📊
Key Findings & Data:Grapefruit juice-statin interactions were first investigated in 1998 in human pharmacokinetic studies with lovastatin and simvastatin.
💡
Conclusion & Impact:Therefore, patients using statins are generally advised to avoid grapefruit juice consumption.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Grapefruit juice · drug interaction · statins

Abstract

Grapefruit juice, which discovered to interact with felodipine for the first time, is now known to interact with more that 80 drugs. Statins are among the drugs that interact with grapefruit juice. Grapefruit juice-statin interactions were first investigated in 1998 in human pharmacokinetic studies with lovastatin and simvastatin. The pharmacokinetic and pharmacodynamic basis of the interaction has been extensively investigated in studies. Flavonoids and furanocoumarins, the main components of grapefruit juice, have been reported to cause drug interactions. Furthermore, statin-grapefruit juice interactions occur mostly through inhibition of cytochrome-3A4 (CYP3A4), to a lesser extent through inhibition of P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATPs). Changes in plasma drug levels as a result of interaction may increase the side-effect of statins or reduce their therapeutic efficacy. Therefore, patients using statins are generally advised to avoid grapefruit juice consumption.

🔖

Cite This Article

ATEŞ, M., ŞAHİN, S. (2023). Interaction of Statins with Grapefruit Juice. Fabad Eczacılık Bilimler Dergisi, Cilt: 48 Sayı: 2, 337–358. https://ajindex.com/articles/958206

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Amly, W., Karaman, R. (2015). Commonly used drugs uses, side effects, bioavailability and approaches to improve it. 1th ed. Nova Science Publishers, USA, 131-172.
  2. Ando, H., Tsuruoka, S., Yanagihara, H., Sugimoto, K.I., Miyata, M., Yamazoe, Y., Takamura, T., Kaneko, S., Fujimura, A. (2005). Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. British Journal of Clinical Pharmacology, 60(5), 494-497. doi: 10.1111/j.1365-2125.2005.02462.x. Bailey, D.G., Spence, J.D., Edgar, B., Bayliff, C.D., Arnold, J.M. (1989). Ethanol enhances the hemodynamic effects of felodipine. Clinical and Investigative Medicine, 12(6), 357-362.
  3. Bailey, D.G., Kreeft, J.H., Munoz, C., Freeman, D.J., Bend, J.R. (1998). Grapefruit juice-felodipine interaction: Effect of naringin and 6’,7’-dihydroxybergamottin in humans. Clinical Pharmacology & Therapeutics, 64(3), 248-256. doi: https://doi.org/10.1016/S0009-9236(98)90173-4.
  4. Bailey, D.G., Dresser, G.K. (2004). Interactions between grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs, 4(5), 281-297. doi: https://doi.org/10.2165/00129784-200404050-00002.
  5. Bailey, D.G. (2010). Fruit juice inhibition of uptake transport: a new type of food–drug interaction. British Journal of Clinical Pharmacology, 70(5), 645-655. doi: 10.1111/j.1365-2125.2010.03722.x Bailey, D.G., Dresser, G., Arnold, M.O. (2013). Grapefruit–medication interactions: Forbidden fruit or avoidable consequences? Canadian Medical Association Journal, 185(4), 309-316. doi: https://doi.org/10.1503/cmaj.120951.
  6. Bang, L.M., Goa, K.L. (2003). Pravastatin a review of its use in elderly patients. Drugs Aging, 20(14), 1061-1082. doi: https://doi.org/10.2165/00002512-200320140-00005.
  7. Bellosta, S., Paoletti, R., Corsini, A. (2004). Safety of statins focus on clinical pharmacokinetics and drug Interactions. Circulation, 109(23), 50-57. doi: 10.1161/01.CIR.0000131519.15067.1f. Bonsu, K.O., Kadirvelu, A., Reidpath, D.D. (2013). Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. Systematic Reviews, 2(22), 1-7. doi: 10.1186/2046-4053-2-22.
  8. Carella, A.M., Marinelli, T., Melfitano, A., Di Pumpo, M., Conte, M., Modola, G., Puntonio, M.C., Benvenuto, A. (2016). Focus on pitavastatin. International Journal of Cardiology and Lipidology Research, 3, 11-19. doi: http://dx.doi.org/10.15379/2410-2822.2016.03.01.03
  9. Carswell, C.I., Plosker, G.L., Jarvis, B. (2002). Rosuv